Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma By Ogkologos - September 21, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final 5-year analysis of overall survival in the IMCgp100-202 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC MOST POPULAR Pattern of DNA Damage Links Colorectal Cancer and Diet High in... July 22, 2021 Five Questions with…Fred. April 14, 2022 Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib... August 21, 2025 Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... March 3, 2021 Load more HOT NEWS Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and... Tobacco-Related Deaths Claim Almost 60,000 Women’s Lives Each Year, And Are... Forging Military Partnerships to Empower the Cancer Research Enterprise Reunión anual de la American Society of Clinical Oncology de 2023:...
